KRAS and cancer: The frequency of KRAS variation in our cohort was 12.4%, which is higher than in The Cancer Genome Atlas and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets cohorts (3.3% and 6.3%, respectively),12,13 possibly due to differences in racial or etiological factors.